CHOLOGRAFIN MEGLUMINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOGRAFIN MEGLUMINE is an injectable diagnostic contrast agent approved in 1954 for radiographic imaging procedures. It is a iodinated organic compound used to visualize biliary and hepatic structures during cholangiography and cholecystography. The drug enhances radiographic contrast in the biliary system to aid in diagnostic imaging.
LOE Approaching
With LOE approaching and zero linked jobs, this legacy diagnostic agent faces declining commercial relevance and minimal team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLOGRAFIN MEGLUMINE offers minimal career advancement potential with zero linked job openings and legacy product status. Professionals on this team would focus on operational continuity and compliance rather than growth or innovation initiatives.
Product Manager (Diagnostics)Regulatory Affairs Specialist
Worked on CHOLOGRAFIN MEGLUMINE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.